Clinical Trial Detail

NCT ID NCT01343043
Title A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients With Synovial Sarcoma (NY-ESO-1)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Adaptimmune
Indications

synovial sarcoma

Therapies

NY-ESO-1-c259T

Age Groups: senior adult child

Additional content available in CKB BOOST